Moldova - rumensk - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

apotex inc. - bisoprololum - comprimate filmate - 10 mg

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - pantoprazole sodium sesquihydrate -

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - pantoprazole sodium sesquihydrate -

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - gabapentin, quantity: 300 mg - capsule - excipient ingredients: lactose monohydrate; maize starch; purified talc; gelatin; purified water; sodium lauryl sulfate; titanium dioxide; iron oxide yellow - gabapentin is indicated for the treatment of partial seizures, including secondarily generalised tonic-clonic seizures, initially as add-on therapy in adults and children age 3 years and above who have not achieved adequate control with standard anti-epileptic drugs. gabapentin is indicated for the treatment of neuropathic pain.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - gabapentin, quantity: 100 mg - capsule - excipient ingredients: lactose monohydrate; maize starch; purified talc; gelatin; purified water; sodium lauryl sulfate; titanium dioxide - gabapentin is indicated for the treatment of partial seizures, including secondarily generalised tonic-clonic seizures, initially as add-on therapy in adults and children age 3 years and above who have not achieved adequate control with standard anti-epileptic drugs. gabapentin is indicated for the treatment of neuropathic pain.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - amoxicillin trihydrate, quantity: 574 mg (equivalent: amoxicillin, qty 500 mg); potassium clavulanate, quantity: 149 mg (equivalent: amoxicillin, qty 500 mg; equivalent: clavulanic acid, qty 125 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; magnesium stearate; purified talc; povidone; triethyl citrate; hypromellose; titanium dioxide; ethylcellulose - short-term treatment of bacterial infection at the following sites when caused by amoxycillin/clavulanic acid sensitive, beta-lactamase producing organisms. skin and skin structure infections. urinary tract infections (uncomplicated and complicated). upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis. lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis. appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoxycillin/clavulanic acid tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed in the microbiological section, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused

Moldova - rumensk - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

apotex inc. - esomeprazolum - comprimate filmate cu eliberare prelungita - 20 mg

Moldova - rumensk - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

apotex inc. - esomeprazolum - comprimate filmate cu eliberare prelungita - 40 mg

Moldova - rumensk - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

apotex inc. - fluconazolum - comprimate - 100 mg

Moldova - rumensk - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

apotex inc. - fluconazolum - comprimate - 50 mg